Allergy Research

Grounded in Science. Designed for Relief.

At AllergyRx, we believe the path to lasting relief begins with understanding. Our Allergy Research reveals the evidence, mechanisms, and purpose behind every ingredient in your custom prescription—so you can move forward with clarity and confidence.

‍

Ingredient Insights: What’s in Your Spray (and Why It Works)

All ingredients are carefully selected by our allergists to target specific symptoms and thoughtfully combined to enhance effectiveness. Explore the research behind our core ingredients and how they work together to help you break free from the limits of allergies.

Drug Class:
Intranasal antihistamine

‍

How it Works:
Azelastine blocks histamine H₁ receptors in the nasal tissues, preventing the cascade of allergic reactions that cause sneezing, itching, runny nose, and mild nasal congestion. It also has mild anti-inflammatory effects, contributing to broader symptom control beyond traditional oral antihistamines.

‍

Quick Stat:
Azelastine provides up to 2x greater symptom relief compared to placebo, with onset of action within 15–30 minutes after administration.

‍

AllergyRx Approach:
At AllergyRx, we integrate azelastine to deliver rapid, targeted antihistamine relief directly to the nasal tissues. When combined with anti-inflammatory and decongestant agents, azelastine helps create a multi-layered defense against allergic symptoms, offering both fast onset and lasting protection.

Drug Class:
Intranasal corticosteroid

‍

How it Works:
Fluticasone reduces inflammation in the nasal passages by blocking the release of inflammatory mediators and decreasing immune cell activity. This action helps relieve nasal congestion, sneezing, itching, and a runny nose. It is considered a first-line treatment for allergic rhinitis because of its broad anti-inflammatory effects across multiple allergy pathways.

‍

Quick Stat:
Fluticasone improves total nasal symptom scores up to 70%, with the greatest impact on nasal congestion.

‍

Relief typically begins within 12–24 hours, with peak effectiveness achieved after 3–5 days of consistent use.

‍

AllergyRx Approach:

At AllergyRx, we harness the powerful anti-inflammatory effects of fluticasone as the foundation of our nasal therapy. By combining it with precision-targeted antihistamines and micro-dosed decongestants, we enhance symptom relief across multiple pathways, delivering fast, sustained, and comprehensive nasal comfort.

How it Works:
Ipratropium blocks muscarinic receptors in the nasal mucosa, reducing glandular secretions and controlling watery nasal discharge (rhinorrhea). By specifically targeting mucus production, ipratropium strengthens overall nasal symptom management alongside antihistamines and corticosteroids.

‍

Quick Stat:
Ipratropium reduces rhinorrhea by approximately 40%, with symptom improvement typically starting within 15 minutes of administration.

‍

AllergyRx Approach:
At AllergyRx, we incorporate ipratropium to enhance the action of our core anti-inflammatory and antihistamine therapies. By directly targeting excessive nasal secretions, ipratropium strengthens overall symptom control, ensuring a more complete and balanced relief experience for patients.

Drug Class:
Mucosal protectant and epithelial restorative agent

‍

How it Works:
Dexpanthenol, a provitamin of B5, promotes hydration, supports epithelial regeneration, and helps maintain the integrity of the nasal mucosa. It enhances natural healing processes, protecting the nasal lining from dryness and irritation.

‍

Quick Stat:
Clinical studies show that dexpanthenol accelerates mucosal healing and can reduce rebound congestion when combined with decongestants.

‍

AllergyRx Approach:
At AllergyRx, we incorporate dexpanthenol to enhance mucosal recovery and resilience. By supporting the health of the nasal lining, dexpanthenol strengthens the long-term effectiveness of our therapies and helps protect patients against irritation associated with allergy treatments and environmental triggers

Drug Class:
Topical nasal decongestant (alpha-adrenergic agonist)

‍

How it Works:
Oxymetazoline constricts blood vessels in the nasal mucosa by activating alpha-adrenergic receptors. This action rapidly reduces swelling, improves airflow, and relieves nasal congestion.

‍

Quick Stat:
Oxymetazoline significantly minimizes nasal blood flow and congestion, even at 1/50th of the standard dose, with onset of relief within 5–10 minutes.

‍

AllergyRx Approach:
At AllergyRx, we utilize precision micro-dosing of oxymetazoline to enhance the decongestant effect, minimizing the risk of rebound congestion and allowing patients to experience fast, sustained nasal relief as part of a broader, multi-symptom treatment strategy.

AllergyRx’s custom sprays blend ingredients to hit multiple symptom targets at once. That’s not just smart—it’s backed by science. Check out the studies showing how combo therapies outperform single-ingredient sprays.

‍

Allergic rhinitis affects an estimated 81 million people in the United States, making it one of the most common chronic conditions. Yet millions of allergy sufferers still rely on single-ingredient nasal sprays that only target one part of the allergy cascade—often leaving symptoms like congestion, sneezing, and excess mucus unresolved.

‍

At AllergyRx, we take a different approach. Our custom combination sprays are designed to act on multiple biological pathways at once—including inflammation, histamine release, vascular swelling, and glandular secretions. By utilizing custom combinations of corticosteroids, antihistamines, anticholinergics, and decongestants, we address the full spectrum of allergic rhinitis symptoms.

‍

And it’s not just smart design—it’s backed by science. Clinical studies consistently show that combination therapy delivers faster symptom relief, greater total control, and sustained long-term effectiveness compared to monotherapy.

Category: Combination Therapy – General
Study Link: JACI Study – Triamcinolone, Azelastine, Oxymetazoline

‍

Overview:
This randomized trial evaluated a single-spray formulation combining a corticosteroid (triamcinolone), an antihistamine (azelastine), and a decongestant (oxymetazoline) in patients with allergic rhinitis. The study aimed to determine whether this integrated delivery system provided superior symptom control compared to monotherapy sprays.

‍

The Takeaways:

• Patients using the triple spray experienced significantly greater sinus pressure relief (p = 0.039) than those on a single therapy.
• No increase in adverse events was reported, suggesting excellent tolerability.
• The combination provided both fast and sustained symptom control.

‍

Why It Matters:

Traditional single-agent sprays often fall short when symptoms span multiple mechanisms (e.g., congestion, inflammation, discharge). This study shows that layering multiple therapeutic targets into one spray provides amplified relief without increasing risk.

‍

The Link to AllergyRx:

AllergyRx formulates triple-mechanism sprays personalized to your exact symptom profile. By customizing ingredients like corticosteroids like fluticasone or, azelastine, and micro-dosed oxymetazoline, we deliver fast, layered relief without sacrificing safety—directly mirroring this study’s findings.

Category: Combination Therapy – General
Study Link: Systematic Review

‍

Overview:
This systematic review analyzed 53 randomized trials comparing combination therapies (e.g., antihistamines + decongestants or corticosteroids + antihistamines) versus monotherapies for allergic rhinitis.

‍

The Takeaways:

• Pairing intranasal antihistamines with corticosteroids  enhanced symptom relief and quality of life.
• Saline irrigation added to drug regimens improved comfort and mucociliary clearance.
• Combination treatments consistently outperformed single-agent therapies across multiple outcome domains.

‍

Why It Matters:
Multisymptom allergic rhinitis demands more than a one-size-fits-all approach. This review confirms that strategic combinations offer broader, deeper symptom control—especially for patients unresponsive to solo agents.

‍

The Link to AllergyRx:
Our treatment philosophy is built on exactly this: synergy over simplicity. We combine complementary actives like antihistamines, corticosteroids, and decongestants in one precision-dose spray, giving you multidimensional relief—validated by the data.

Category: Combination Therapy – Antihistamine + Corticosteroid
Study Link: PubMed – Azelastine + Fluticasone

‍

Overview:
This 14-day, multicenter trial tested the efficacy of azelastine (antihistamine) and fluticasone (corticosteroid) delivered together in a single spray. Patients had moderate-to-severe seasonal allergic rhinitis during the Texas mountain cedar season.

‍

The Takeaways:

• The combination group had the greatest symptom score reduction (28.4%) vs fluticasone alone (20.4%), azelastine alone (16.4%), and placebo (11.2%).
• No new safety concerns were reported; the combo was as well-tolerated as monotherapies. 

‍

Why It Matters:
When symptoms like sneezing, itching, and congestion hit at once, layering anti-inflammatory and antihistaminic action is more effective than relying on one agent.

‍

The Link to AllergyRx:
AllergyRx offers customizable dual-spray combinations like azelastine + corticosteroid, tuned to your unique triggers. This study validates our design: faster, deeper symptom relief—without added burden or risk.

‍

Azelastine + Fluticasone Combination Outperforms Single Agents https://pubmed.ncbi.nlm.nih.gov/20674829/

‍

Overview:
In a randomized, double-blind study of 610 patients with moderate-to-severe seasonal allergic rhinitis, a combination nasal spray containing azelastine and fluticasone was compared to each ingredient alone and to placebo over 14 days. The combination spray improved total nasal symptom scores better than with fluticasone alone or with azelastine alone. All treatments were well tolerated, with no increase in side effects.

‍

Why It Matters:
When symptoms like sneezing, itching, and congestion hit at once, layering anti-inflammatory and antihistaminic action is more effective than relying on one agent.

‍

The combination spray delivered 39% greater symptom relief than fluticasone alone, and an impressive 73% greater relief than azelastine alone.
 

The Link to AllergyRx: 

By targeting multiple allergy pathways simultaneously, patients experience stronger, faster, and broader symptom control than with single-agent therapies. AllergyRx offers customizable dual-spray combinations like azelastine + corticosteroid, tuned to your unique triggers.

Category: Combination Therapy – Decongestant + Corticosteroid

Study Link: JACI Study – Fluticasone + Oxymetazoline

‍

Overview:
This study compared fluticasone alone, oxymetazoline alone, and a combo of both over 4 weeks of nightly use. It tracked nasal congestion, airflow, and quality of life in patients with allergic rhinitis.

‍

The Takeaways:

• Combo therapy significantly outperformed fluticasone alone in reducing congestion and increasing nasal volume.
• No rebound congestion or tolerance (tachyphylaxis) was observed, even after 4 weeks of oxymetazoline use.
• The combination was well tolerated across the board. 

‍

Why It Matters:
There’s long-standing hesitation around decongestant use due to fear of rebound symptoms. This study proves that when paired with a corticosteroid, oxymetazoline is not only more effective—it’s also safe for longer-term use.

‍

The Link to AllergyRx:
This study validates our dual-mechanism approach—pairing a topical steroid with a micro-dosed decongestant to maximize symptom control while minimizing rebound effects. The difference? We personalize the dose to you.

Category: Micro-Dosed Decongestant
Study Link: PubMed – Oxymetazoline Dose Response

‍

Overview:
This dose-response study tested various concentrations of the intranasal decongestant oxymetazoline in healthy adults. Researchers measured changes in nasal airway resistance, cross-sectional area swelling, volume, and the study patients' feeling of congestion.

‍

The Takeaways:

• Even 6.25 micrograms of oxymetazoline, a fraction of standard doses, improved nasal volume and patency.
• Higher doses offered more resistance relief, but even the lowest doses created measurable airflow benefits.
• No serious side effects or significant differences in symptom perception were observed across doses. 

‍

Why It Matters:
You don’t need high doses to see results. This study validates the use of ultra-low doses of oxymetazoline for effective decongestion—minimizing risks like dryness, tolerance, or dependency.

‍

The Link to AllergyRx:
Our sprays feature precision micro-doses of oxymetazoline—engineered to unlock airflow without triggering rebound congestion or irritation. It’s relief that’s effective, but never aggressive.

Category: Combination Therapy – Decongestant + Corticosteroid
Study Link: PubMed – Fluticasone and Oxymetazoline

‍

Overview:
This randomized crossover study explored whether fluticasone could reverse rebound congestion and tachyphylaxis (diminished response) after 14 days of repeated oxymetazoline use. Healthy adults were monitored for nasal airflow and congestion symptoms during and after treatment.

‍

The Takeaways:

• Fluticasone **restored nasal airflow** and responsiveness after oxymetazoline tolerance had developed.
• No rebound congestion occurred in the fluticasone group.
• Results show **steroid pairing helps prevent and reverse** decongestant side effects.

‍

Why It Matters:

One of the biggest myths in nasal care is that all decongestants inevitably lead to rebound congestion. This study proves that a smart combination—decongestant + steroid—can both protect and reset the nasal mucosa.

‍

The Link to AllergyRx:
Pairing a steroid, like fluticasone, with oxymetazoline helps prevent and reverse tolerance and rebound congestion. At AllergyRx, we apply this principle using micro-dosed oxymetazoline alongside fluticasone—ensuring safe, long-term congestion relief without the risk of overuse or diminished response.

Category: Anti-Discharge
Study Link: PubMed – Ipratropium in PAR

‍

Overview:
This double-blind trial evaluated the use of ipratropium bromide, an intranasal anticholinergic, for treating rhinorrhea (runny nose) in patients with perennial allergic rhinitis. Two different doses were tested over 8 weeks.

‍

The Takeaways:

• Both 42 mcg and 84 mcg doses significantly reduced nasal secretions compared to placebo.
• The effects were sustained over 8 weeks.
• No rebound symptoms or safety concerns were reported.

‍

Why It Matters:
While corticosteroids and antihistamines are great for itching and congestion, they often miss the mark on watery discharge. Ipratropium provides targeted control for this specific, oftenoverlooked symptom.

‍

The Link to AllergyRx:
If your allergy experience involves constant nasal drip, we’ve got a solution. Our custom sprays may include ipratropium, giving you dedicated anti-discharge support—so your tissues can take the day off.

Category: Combination Therapy – Anti-Discharge + Corticosteroid
Study Link: PubMed – Ipratropium + Beclomethasone

‍

Overview:
This placebo-controlled study looked at the effectiveness of combining ipratropium bromide (anti-discharge) with beclomethasone (steroid) in a single nasal spray, against either in a single ingredient spray for patients with perennial rhinitis over four weeks.

‍

The Takeaways:

• ‍The combination of ipratropium and beclomethasone nasal spray was more effective than either agent monotherapy. The dual therapy provided a faster onset for runny nose due to the ipratropium component and reduction of severity of nasal inflammation and sneezing provided by the beclomethasone.

‍

Why It Matters:
Most patients don’t experience just one symptom—so why treat just one? This study confirms that addressing inflammation and secretions together is a smarter, more complete strategy.

‍

The Link to AllergyRx:
While beclomethasone was used here, AllergyRx prefers luticasone as our corticosteroid of choice due to its proven recognition as a first-line treatment. What this study reinforces is the value of dual-action therapy: we combine anti-inflammatory support with agents like ipratropium bromide when runny nose is a significant symptom. The result is a more complete solution, customized to your primary triggers.

Category: Nasal Saline
Study Link: PMC – Saline Irrigation Meta-Analysis

‍

Overview:
This meta-analysis reviewed 10 randomized controlled trials evaluating nonpharmacological saline irrigation as an adjunct to medication therapy for allergic rhinitis. Measured outcomes included symptom reduction, medication use, mucociliary clearance, and quality of life.

‍

The Takeaways:

• Saline irrigation improved symptoms by 27.7% and reduced medication use by over 60%.
• Mucociliary clearance improved by 31%, supporting airway hygiene.
• Routine use was safe and effective without adverse effects** over  the study period.

‍

Why It Matters:
Saline isn’t just a gentle rinse—it’s a proven nonpharmacological tool to boost overall treatment outcomes,  improve the effectiveness of allergy medications, and improve nasal function. Especially useful in sensitive patients or children.

‍

The Link to AllergyRx:
We often recommend nasal saline as a baseline therapy to promote healthy nasal airways. It’s an easy, affordable way to complement your personalized AllergyRx formulation.

Category: Micro-Dosed Decongestant
Study Link: PubMed – 4 Weeks of Oxymetazoline

‍

Overview:
This 4-week study followed healthy adults using oxymetazoline 3x daily—far more than what AllergyRx provides—to assess for rebound congestion or tolerance (tachyphylaxis).

‍

The Takeaways:

• There was **no significant rebound congestion** observed in any participants.
• Nasal function metrics, airflow volume, airway resistances, and flow remained stable, and congestion scores stayed low.
• Oxymetazoline continued to work throughout the study with **no loss of efficacy**. 

‍

Why It Matters:
This is the study that flips the script: oxymetazoline, when used thoughtfully,  does not demonstrate rebound congestion or tolerance, a previous common concern. With micro-doses and the right co-formulations, it’s a safe, long-term congestion solution.

‍

The Link to AllergyRx:
Your congestion deserves relief without the rebound. That’s why we use fractional dosing of oxymetazoline—strategically calibrated for maxium effectiveness while minimizing the risk of rebound congestion. It’s targeted intelligent therapy designed for lasting comfort.

Category: Combination Therapy – Decongestant + Corticosteroid
Study Link: PMC – Fixed-Dose Fluticasone/Oxy Combo

‍

Overview:
This multicenter trial  compared the use of the combination of fluticasone furoate (27.5 mcg) + oxymetazoline (50 mcg) nasal spray with fluticasone furoate 27.5mcg alone. Study patients with moderate-to-severe allergic rhinitis and congestion were treated with the steroid or steroid and decongestant therapy nightly for 28 days.

‍

The Takeaways:

• Symptom improvement started as early as **Day 3**, with full  Total Nasal Symptom Scores significantly reduced by Day 28.
• Nearly 45% of patients experienced complete nasal congestion relief.
• No signs of rebound congestion were observed, even after a full month of oxymetazoline use. 

‍

Why It Matters:
This isn’t just a study—it’s a proof-of-concept for fixed, synergistic dosing that works fast, works consistently, and works safely. That’s the kind of data you want behind your allergy care.

‍

The Link to AllergyRx:
This fixed-dose combo proves that steroids + decongestants work better together. At AllergyRx, we custom-compound this concept—using fluticasone and micro-dosed oxymetazoline, personalized for your symptom severity and frequency. We don’t believe in one-size-fits-all sprays—only in smart, safe solutions built around you.

Category: Combination Therapy – Decongestant + Corticosteroid
Study Link: PubMed – 15-Day Oxymetazoline + MFNS Trial

‍

Overview:
This large Phase 2 trial tested short-term use (15 days) of mometasone + oxymetazoline—once or three times daily—against monotherapy and placebo in 705 teens and adults with seasonal allergic rhinitis.

‍

The Takeaways:

• Combination treatments **outperformed monotherapy and placebo** across all rhinitis symptoms —especially nasal congestion.
• Day 1 relief was significantly greater in the combination group.
• The treatment was well tolerated, with no rebound effects or serious adverse events.

‍

Why It Matters:
The faster you control inflammation and congestion, the faster your life goes back to normal. This study proves you can have relief on day one without the fear of rebound effects.

‍

The Link to AllergyRx:
This study affirms our strategy of combining a nasal steroid with micro-dosed oxymetazoline decongestant provides fast, safe, effective treatment for your allergy needs.

Category: Monotherapy – Corticosteroid
‍Study Link: PubMed

‍

Overview:
This network meta-analysis evaluated the comparative efficacy and acceptability of licensed-dose aqueous intranasal corticosteroids (INCSs) for treating moderate-to-severe allergic rhinitis (AR). The study synthesized data from 26 randomized controlled trials, including 5,134 patients with seasonal allergic rhinitis (SAR)and 4,393 participants with perennial allergic rhinitis (PAR), to determine if any INCS were superior in efficacy or tolerability.

‍

The Takeaways:

• No single INCS demonstrated superior efficacy over others in treating AR.
• All evaluated INCSs were well-tolerated with similar safety profiles.
• The choice of INCS can be guided by patient preference, cost, and availability rather than efficacy differences.

‍

The study results demonstrated that all nasal corticosteroids included were significantly superior to placebo. Mometasone had the highest efficacy in improving Total Nasal Symptom Scores (TNSS), followed by fluticasone for patients with SAR. Beclomethasone followed by fluticasone was superior in treating TNSS for PAR patients. Fluticasone ranked the highest in the improvement of ocular allergy symptoms. 

‍

Why It Matters:
Understanding that various nasal corticosteroids are effective in improving nasal symptoms allows for flexibility in prescribing, focusing on patient-specific factors to enhance adherence and satisfaction.

‍

The Link to AllergyRx:
AllergyRx selects from a range of clinically equivalent corticosteroids—like triamcinolone or fluticasone—based on your needs and tolerability, mirroring this study’s findings.

Category: Monotherapy – Antihistamine
‍Study Link: PMC

‍

Overview:
This study assessed the effectiveness of the azelastine nasal spray in patients with allergic rhinitis, particularly focusing on its impact on nasal congestion and overall symptom relief.

‍

The Takeaways:

• Azelastine nasal spray significantly reduced nasal congestion and post-nasal drip compared to placebo.
• Compared to oral antihistamines, azelastine demonstrated a rapid onset of action and superior efficacy.
• Well-tolerated with minimal adverse effects reported. The study also found that the combination of azelastine and fluticasone was superior in effectiveness than either agent alone.

‍

Why It Matters:
Azelastine offers a valuable treatment option for allergic rhinitis patients, especially those who do not achieve adequate relief from oral antihistamines. Combined with fluticasone, even greater relief can be achieved. 

‍

The Link to AllergyRx:
Incorporating azelastine into AllergyRx formulations provides targeted antihistaminic action, enhancing symptom control for patients with predominant nasal congestion.

Category: Monotherapy – Anticholinergic
‍Study Link: PubMed

‍

Overview:
This open-label, 12-month clinical trial evaluated the long-term safety and efficacy of ipratropium bromide nasal spray 0.06% in patients with perennial allergic rhinitis (PAR), focusing on its effect on rhinorrhea (runny nose).

‍

The Takeaways:

• Significant reduction in rhinorrhea observed throughout the study period.
• Improved control of sneezing, post-nasal drip, and congestion. Well-tolerated with minimal adverse events, supporting its long-term use.

‍

Why It Matters:
Effective management of rhinorrhea is crucial for PAR patients, and ipratropium bromide offers a safe long-term treatment option.

‍

The Link to AllergyRx:
AllergyRx can include ipratropium bromide in personalized nasal spray formulations to address persistent rhinorrhea, enhancing overall symptom relief.

Category: Combination Therapy – Decongestant + Mucosal Protective Agent
Study Link: PubMed

‍

Overview:
This investigator-blind, randomized, controlled phase IV clinical trial evaluated the efficacy and safety of a nasal spray combining oxymetazoline 0.05% (a decongestant) with dexpanthenol 5% (a mucosal protective agent) compared to xylometazoline 0.1% in 100 patients suffering from acute allergic rhinitis or post-nasal surgery congestion. PubMed+1Europe PMC+1

‍

The Takeaways:

• The combination therapy provided significantly better relief from nasal congestion, sneezing, and nasal discharge than xylometazoline alone.
  
• Patients experienced a shorter recovery time (1.08 hours vs. 1.86 hours) with the combination therapy.
  
• Incidence of rebound congestion was markedly lower in the combination group (6.25%) compared to the xylometazoline group (82.98%).
  
• The combination therapy was better tolerated, with 95.83% of patients rating tolerability as good to excellent, versus 52.91% in the xylometazoline group. PubMed
  
  

Why It Matters:
Combining a decongestant with a mucosal protective agent like dexpanthenol can enhance symptom relief, reduce the risk of rebound congestion, and improve overall tolerability in patients with nasal congestion due to allergic rhinitis or post-surgical conditions.

‍

The Link to AllergyRx:
AllergyRx leverages such combination therapies in customized formulations, balancing efficacy and safety to meet individual patient needs.

Category: Supportive Therapy – Mucosal Protective Agent + Decongestant
Study Link: PubMed

‍

Overview:
This review article explores the role of dexpanthenol, a derivative of pantothenic acid (vitamin B5), in enhancing symptom relief when combined with decongestant nasal sprays for the treatment of acute rhinitis. The study discusses dexpanthenol's properties in promoting mucosal healing and its potential benefits in mitigating the adverse effects associated with prolonged decongestant use.

‍

The Takeaways:

• Mucosal Healing: Dexpanthenol exhibits properties that support the regeneration and maintenance of nasal mucosa, potentially reducing irritation and dryness caused by decongestants.
  
• Enhanced Symptom Relief: When used alongside decongestant sprays, dexpanthenol may improve overall symptom relief in acute rhinitis by addressing both congestion and mucosal health.
  
• Safety Profile: The combination is generally well-tolerated, with dexpanthenol contributing to a favorable safety profile by counteracting the drying effects of decongestants.
  
  

Why It Matters:
Incorporating dexpanthenol into decongestant therapy regimens may offer a more comprehensive approach to managing acute rhinitis, addressing not only nasal congestion but also promoting mucosal integrity and comfort.

‍

The Link to AllergyRx:
AllergyRx recognizes the importance of mucosal health in allergic conditions and may consider formulations that combine decongestants with mucosal protective agents like dexpanthenol to enhance patient outcomes and comfort.

Category: Monotherapy – Antihistamine
‍Study Link: Annals of Allergy, Asthma & Immunology

‍

Overview:
This study assessed the onset of action and overall efficacy of azelastine hydrochloride 0.15% nasal spray in relieving symptoms of allergic rhinitis.

‍

The Takeaways:

• Demonstrated symptom relief within 30 minutes of administration.
• Effective in reducing both nasal and non-nasal symptoms associated with allergic rhinitis.
• Maintained a favorable safety profile throughout the study.

‍

Why It Matters:
Rapid symptom relief is essential for patient comfort and adherence, and azelastine hydrochloride 0.15% offers a prompt therapeutic effect.

‍

The Link to AllergyRx:
Incorporating azelastine hydrochloride into AllergyRx's personalized nasal sprays ensures quick relief for patients, enhancing satisfaction and treatment outcomes.